Pain Clinical Trial
Official title:
[S,S]-Reboxetine Dose-Range Finding Trial: A 16-Week, Randomized, Double-Blind, Placebo And An Active Comparator Controlled, Multi-Center Trial Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN)
Verified date | June 2011 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to determine the effectiveness of different doses of [S,S]-Reboxetine in the treatment of chronic pain following a shingles infection
Status | Completed |
Enrollment | 280 |
Est. completion date | February 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients must have pain present for more than 3 months after the healing of shingles skin rash - Patients at screening must have a score >/=40 mm on the pain visual analogue scale Exclusion Criteria: - Patients with significant renal and hepatic impairment - Patients with other severe pain, that may impair the self-assessment of the pain due to shingles - Patients with clinically abnormal electrocardiogram |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Pfizer Investigational Site | Albany | New York |
United States | Pfizer Investigational Site | Allentown | Pennsylvania |
United States | Pfizer Investigational Site | Altoona | Pennsylvania |
United States | Pfizer Investigational Site | Amherst | New York |
United States | Pfizer Investigational Site | Ann Arbor | Michigan |
United States | Pfizer Investigational Site | Arcadia | California |
United States | Pfizer Investigational Site | Asheville | North Carolina |
United States | Pfizer Investigational Site | Austin | Texas |
United States | Pfizer Investigational Site | Billings | Montana |
United States | Pfizer Investigational Site | Boston | Massachusetts |
United States | Pfizer Investigational Site | Boulder | Colorado |
United States | Pfizer Investigational Site | Bradenton | Florida |
United States | Pfizer Investigational Site | Brockton | Massachusetts |
United States | Pfizer Investigational Site | Canfield | Ohio |
United States | Pfizer Investigational Site | Chandler | Arizona |
United States | Pfizer Investigational Site | Chicago | Illinois |
United States | Pfizer Investigational Site | Cincinnati | Ohio |
United States | Pfizer Investigational Site | Clearwater | Florida |
United States | Pfizer Investigational Site | Cleveland | Ohio |
United States | Pfizer Investigational Site | Clifton | New Jersey |
United States | Pfizer Investigational Site | Columbus | Ohio |
United States | Pfizer Investigational Site | Dallas | Texas |
United States | Pfizer Investigational Site | Duncansville | Pennsylvania |
United States | Pfizer Investigational Site | Evansville | Indiana |
United States | Pfizer Investigational Site | Fargo | North Dakota |
United States | Pfizer Investigational Site | Ft. Myers | Florida |
United States | Pfizer Investigational Site | Fullerton | California |
United States | Pfizer Investigational Site | Hackensack | New Jersey |
United States | Pfizer Investigational Site | Holly Hill | Florida |
United States | Pfizer Investigational Site | Hollywood | Florida |
United States | Pfizer Investigational Site | Hot Springs | Arkansas |
United States | Pfizer Investigational Site | Houston | Texas |
United States | Pfizer Investigational Site | Huntsville | Alabama |
United States | Pfizer Investigational Site | Independence | Missouri |
United States | Pfizer Investigational Site | Irvine | California |
United States | Pfizer Investigational Site | Jackson | Tennessee |
United States | Pfizer Investigational Site | Kansas City | Missouri |
United States | Pfizer Investigational Site | Kettering | Ohio |
United States | Pfizer Investigational Site | Kingsport | Tennessee |
United States | Pfizer Investigational Site | Kissimmee | Florida |
United States | Pfizer Investigational Site | Laguna Hills | California |
United States | Pfizer Investigational Site | Largo | Florida |
United States | Pfizer Investigational Site | Loma Linda | California |
United States | Pfizer Investigational Site | Longwood | Florida |
United States | Pfizer Investigational Site | Melbourne | Florida |
United States | Pfizer Investigational Site | Mesa | Arizona |
United States | Pfizer Investigational Site | New York | New York |
United States | Pfizer Investigational Site | Nixa | Missouri |
United States | Pfizer Investigational Site | Norfolk | Virginia |
United States | Pfizer Investigational Site | Oak Brook | Illinois |
United States | Pfizer Investigational Site | Ocala | Florida |
United States | Pfizer Investigational Site | Oklahoma City | Oklahoma |
United States | Pfizer Investigational Site | Orange | California |
United States | Pfizer Investigational Site | Orchard Park | New York |
United States | Pfizer Investigational Site | Oviedo | Florida |
United States | Pfizer Investigational Site | Palm Beach Gardens | Florida |
United States | Pfizer Investigational Site | Phoenix | Arizona |
United States | Pfizer Investigational Site | Plantation | Florida |
United States | Pfizer Investigational Site | Raleigh | North Carolina |
United States | Pfizer Investigational Site | Redondo Beach | California |
United States | Pfizer Investigational Site | Richmond | Virginia |
United States | Pfizer Investigational Site | Rochester | New York |
United States | Pfizer Investigational Site | Ruston | Louisiana |
United States | Pfizer Investigational Site | San Antonio | Texas |
United States | Pfizer Investigational Site | Sante Fe | New Mexico |
United States | Pfizer Investigational Site | Seattle | Washington |
United States | Pfizer Investigational Site | Southaven | Mississippi |
United States | Pfizer Investigational Site | Spokane | Washington |
United States | Pfizer Investigational Site | Sprinfield | Missouri |
United States | Pfizer Investigational Site | St. Louis | Missouri |
United States | Pfizer Investigational Site | Sun City | Arizona |
United States | Pfizer Investigational Site | Tacoma | Washington |
United States | Pfizer Investigational Site | Teaneck | New Jersey |
United States | Pfizer Investigational Site | Toledo | Ohio |
United States | Pfizer Investigational Site | Topeka | Kansas |
United States | Pfizer Investigational Site | Towson | Maryland |
United States | Pfizer Investigational Site | Tucson | Arizona |
United States | Pfizer Investigational Site | Whittier | California |
United States | Pfizer Investigational Site | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The numerical pain intensity rating scale is used to assess pain and a change from baseline in pain score for week 14 will be calculated | |||
Secondary | - The mean endpoint (week 14) sleep interference score change from baseline - Analysis of the Medical Outcomes Study Sleep Scale - Analysis of the Patient Global Impression of Change - Analysis of the SF-36 Health Survey |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05559255 -
Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI
|
N/A | |
Terminated |
NCT04356352 -
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
|
Phase 2/Phase 3 | |
Completed |
NCT04748367 -
Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care
|
N/A | |
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04466111 -
Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
|
||
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05868122 -
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
|
Phase 3 | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Completed |
NCT03273114 -
Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain
|
N/A | |
Enrolling by invitation |
NCT06087432 -
Is PNF Application Effective on Temporomandibular Dysfunction
|
N/A | |
Completed |
NCT05508594 -
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001
|
Phase 2/Phase 3 | |
Recruiting |
NCT03646955 -
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03472300 -
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
|
||
Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
Completed |
NCT03286543 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System
|
N/A | |
Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
Completed |
NCT02913027 -
Can We Improve the Comfort of Pelvic Exams?
|
N/A | |
Terminated |
NCT02181387 -
Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?
|
Phase 4 | |
Recruiting |
NCT06032559 -
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
|
Phase 3 | |
Active, not recruiting |
NCT03613155 -
Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care
|